MetaCap

Hemab Therapeutics (COAG) vs Lycia Therapeutics (LYCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Hemab Therapeutics is the larger company by market cap ($1.84 billion vs $1.72 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COAG+14.22%LYCA+10.23%
+45%+13%-19%
Oct 23, 20261 yearNov 20, 2026
COAG+14.22%LYCA+10.23%
+45%+15%-15%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COAG versus LYCA key metrics
MetricCOAGLYCA
Share price$39.29$33.07
Market cap$1.84B$1.72B
1-day change-1.43%+4.09%
EPS (TTM)$-3.55$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$55.42$36.49
52-week low$23.00$22.19
Distance from 52-week high-29.11%-9.37%
Analyst consensusstrong_buy—
Avg. price target upside+60.35%—
Average volume495.96K432.72K
Shares outstanding46.73M52.09M
Employees5931
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Hemab Therapeutics

COAG stock →

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

COAG vs LYCA FAQ

Which is bigger, Hemab Therapeutics or Lycia Therapeutics?

Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.84B compared with $1.72B for Lycia Therapeutics (LYCA).

Are Hemab Therapeutics and Lycia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons